Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
posted on
Mar 01, 2024 12:47PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
At the end of the day, there are valid reasons on both sides to be extremely frustrated with managment of both companies for an exit strategy, buyout or partnership deal and or listing not happening as of yet as well as those on the other side who are still optismistic of something coming to fruition at some point in the next few years and are willing to wait it out... The way I look at it is there a several very very large BP's and very highly respected institutions still actively involed in the clinical trials and if the trials move forward they will IMO get involved at much higher level.. IE a BP deal of some sort.. Royalty, Buyout partnership etc. Where management has succeeded with get those clincal collalbations paid for they have failed in establishing on the market valuation for Zenith to this point all working in the BP's favour if they strike a deal at some point . Hopefully we'll be pleasantly surprise with some realy really godd news, I don't see a deal as the market is sayng otherwise , until then we wait it out or we exit ....